Cancer Firm Lands One of Europe’s Biggest Biotech Funding Rounds
This article is for subscribers only.
The German cancer-treatment researcher BioNTech AG raised $325 million from investors, one of the largest financing rounds ever by a European biotechnology company.
The second-round haul brings closely held BioNTech’s total fundraising to more than $1.4 billion, according to Sean Marett, the company’s chief business officer. The figure is high even by standards in the U.S., where the valuations of early-stage drug companies tend to dwarf those of their European counterparts.